Annual CFF
$172.13 M
-$253.62 M-59.57%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual cash flow from financing activities is currently $172.13 million, with the most recent change of -$253.62 million (-59.57%) on 31 December 2023. During the last 3 years, it has fallen by -$1.07 billion (-86.20%). ALNY annual CFF is now -86.20% below its all-time high of $1.25 billion, reached on 31 December 2021.ALNY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$102.75 M
-$28.74 M-21.86%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly cash flow from financing activities is currently $102.75 million, with the most recent change of -$28.74 million (-21.86%) on 30 September 2024. Over the past year, it has increased by +$63.53 million (+161.94%). ALNY quarterly CFF is now -85.71% below its all-time high of $718.88 million, reached on 31 March 2014.ALNY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$302.39 M
+$69.62 M+29.91%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM cash flow from financing activities is currently $302.39 million, with the most recent change of +$69.62 million (+29.91%) on 30 September 2024. Over the past year, it has increased by +$130.26 million (+75.67%). ALNY TTM CFF is now -75.75% below its all-time high of $1.25 billion, reached on 31 December 2021.ALNY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +161.9% | +75.7% |
| 3 y3 years | -86.2% | -64.8% | -75.8% |
| 5 y5 years | -79.1% | +154.7% | -63.3% |
ALNY Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -86.2% | at low | -65.4% | +255.4% | -75.8% | +95.5% |
| 5 y | 5 years | -86.2% | at low | -85.1% | +255.4% | -75.8% | +95.5% |
| alltime | all time | -86.2% | >+9999.0% | -85.7% | +596.4% | -75.8% | >+9999.0% |
Alnylam Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $102.75 M(-21.9%) | $302.39 M(+29.9%) |
| June 2024 | - | $131.50 M(+354.8%) | $232.77 M(+50.5%) |
| Mar 2024 | - | $28.91 M(-26.3%) | $154.67 M(-10.1%) |
| Dec 2023 | $172.13 M(-59.6%) | $39.23 M(+18.4%) | $172.13 M(-12.3%) |
| Sept 2023 | - | $33.14 M(-37.9%) | $196.34 M(-57.3%) |
| June 2023 | - | $53.39 M(+15.1%) | $460.23 M(+5.3%) |
| Mar 2023 | - | $46.37 M(-26.9%) | $437.17 M(+2.7%) |
| Dec 2022 | $425.75 M(-65.9%) | $63.44 M(-78.6%) | $425.75 M(-35.0%) |
| Sept 2022 | - | $297.02 M(+879.1%) | $654.61 M(-29.7%) |
| June 2022 | - | $30.34 M(-13.2%) | $931.42 M(-24.3%) |
| Mar 2022 | - | $34.96 M(-88.0%) | $1.23 B(-1.3%) |
| Dec 2021 | $1.25 B(+25.3%) | $292.29 M(-49.1%) | $1.25 B(+6.3%) |
| Sept 2021 | - | $573.84 M(+74.0%) | $1.17 B(+85.2%) |
| June 2021 | - | $329.81 M(+544.5%) | $633.09 M(-36.2%) |
| Mar 2021 | - | $51.18 M(-76.5%) | $992.29 M(-0.3%) |
| Dec 2020 | $994.98 M(+20.9%) | $217.95 M(+538.3%) | $994.98 M(+21.7%) |
| Sept 2020 | - | $34.15 M(-95.0%) | $817.37 M(+7.2%) |
| June 2020 | - | $689.01 M(+1179.1%) | $762.52 M(+56.9%) |
| Mar 2020 | - | $53.87 M(+33.5%) | $486.12 M(-40.9%) |
| Dec 2019 | $823.18 M(+1157.3%) | $40.34 M(-294.9%) | $823.18 M(+4.4%) |
| Sept 2019 | - | -$20.70 M(-105.0%) | $788.22 M(-4.1%) |
| June 2019 | - | $412.61 M(+5.5%) | $821.91 M(+98.1%) |
| Mar 2019 | - | $390.93 M(+7169.1%) | $414.88 M(+533.7%) |
| Dec 2018 | $65.47 M(-94.2%) | $5.38 M(-58.6%) | $65.47 M(-91.5%) |
| Sept 2018 | - | $12.99 M(+132.7%) | $767.04 M(-2.0%) |
| June 2018 | - | $5.58 M(-86.6%) | $782.97 M(-32.7%) |
| Mar 2018 | - | $41.52 M(-94.1%) | $1.16 B(+3.4%) |
| Dec 2017 | $1.12 B(+532.6%) | $706.95 M(+2344.9%) | $1.12 B(+167.2%) |
| Sept 2017 | - | $28.91 M(-92.5%) | $421.02 M(+6.2%) |
| June 2017 | - | $386.31 M(>+9900.0%) | $396.46 M(+141.0%) |
| Mar 2017 | - | $2.72 M(-11.9%) | $164.48 M(-7.5%) |
| Dec 2016 | $177.83 M(-71.1%) | $3.08 M(-29.1%) | $177.83 M(-1.9%) |
| Sept 2016 | - | $4.35 M(-97.2%) | $181.22 M(+0.4%) |
| June 2016 | - | $154.34 M(+860.6%) | $180.52 M(+442.8%) |
| Mar 2016 | - | $16.07 M(+148.4%) | $33.26 M(-94.6%) |
| Dec 2015 | $616.18 M(-16.3%) | $6.47 M(+77.2%) | $616.18 M(-0.2%) |
| Sept 2015 | - | $3.65 M(-48.4%) | $617.37 M(-0.2%) |
| June 2015 | - | $7.07 M(-98.8%) | $618.51 M(+0.3%) |
| Mar 2015 | - | $598.98 M(+7721.7%) | $616.57 M(-16.3%) |
| Dec 2014 | $736.47 M | $7.66 M(+59.7%) | $736.47 M(+0.0%) |
| Sept 2014 | - | $4.79 M(-6.7%) | $736.46 M(-0.8%) |
| June 2014 | - | $5.14 M(-99.3%) | $742.75 M(+0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $718.88 M(+9297.1%) | $741.59 M(+269.1%) |
| Dec 2013 | $200.93 M(+115.1%) | $7.65 M(-31.0%) | $200.93 M(+3.4%) |
| Sept 2013 | - | $11.08 M(+178.4%) | $194.24 M(+3.5%) |
| June 2013 | - | $3.98 M(-97.8%) | $187.66 M(+1.8%) |
| Mar 2013 | - | $178.21 M(>+9900.0%) | $184.30 M(+97.3%) |
| Dec 2012 | $93.41 M(>+9900.0%) | $966.00 K(-78.5%) | $93.41 M(+0.8%) |
| Sept 2012 | - | $4.50 M(+616.4%) | $92.71 M(+5.1%) |
| June 2012 | - | $628.00 K(-99.3%) | $88.21 M(+0.2%) |
| Mar 2012 | - | $87.32 M(>+9900.0%) | $88.05 M(>+9900.0%) |
| Dec 2011 | $738.00 K(-79.9%) | $267.00 K(>+9900.0%) | $738.00 K(-26.1%) |
| Sept 2011 | - | $0.00(-100.0%) | $998.00 K(-5.0%) |
| June 2011 | - | $462.00 K(+5033.3%) | $1.05 M(-66.4%) |
| Mar 2011 | - | $9000.00(-98.3%) | $3.13 M(-14.6%) |
| Dec 2010 | $3.66 M(+4.4%) | $527.00 K(+894.3%) | $3.66 M(-2.9%) |
| Sept 2010 | - | $53.00 K(-97.9%) | $3.77 M(-15.8%) |
| June 2010 | - | $2.54 M(+368.8%) | $4.48 M(+16.7%) |
| Mar 2010 | - | $542.00 K(-14.6%) | $3.84 M(+9.5%) |
| Dec 2009 | $3.51 M(+11.2%) | $635.00 K(-16.8%) | $3.51 M(-675.2%) |
| Sept 2009 | - | $763.00 K(-59.9%) | -$610.00 K(-360.7%) |
| June 2009 | - | $1.90 M(+805.2%) | $234.00 K(-93.9%) |
| Mar 2009 | - | $210.00 K(-106.0%) | $3.84 M(+21.6%) |
| Dec 2008 | $3.15 M(-94.6%) | -$3.48 M(-316.8%) | $3.15 M(-57.3%) |
| Sept 2008 | - | $1.61 M(-70.8%) | $7.39 M(-88.4%) |
| June 2008 | - | $5.50 M(-1266.1%) | $63.76 M(+8.9%) |
| Mar 2008 | - | -$472.00 K(-162.5%) | $58.56 M(-0.1%) |
| Dec 2007 | $58.63 M(-64.8%) | $755.00 K(-98.7%) | $58.63 M(-63.3%) |
| Sept 2007 | - | $57.97 M(>+9900.0%) | $159.58 M(+56.1%) |
| June 2007 | - | $303.00 K(-176.5%) | $102.22 M(-1.5%) |
| Mar 2007 | - | -$396.00 K(-100.4%) | $103.75 M(-37.7%) |
| Dec 2006 | $166.63 M(+216.7%) | $101.70 M(>+9900.0%) | $166.63 M(+42.3%) |
| Sept 2006 | - | $617.00 K(-66.4%) | $117.09 M(+0.8%) |
| June 2006 | - | $1.84 M(-97.1%) | $116.13 M(+1.4%) |
| Mar 2006 | - | $62.48 M(+19.8%) | $114.50 M(+117.6%) |
| Dec 2005 | $52.62 M(+3.2%) | $52.15 M(<-9900.0%) | $52.62 M(+777.8%) |
| Sept 2005 | - | -$343.00 K(-265.7%) | $5.99 M(-20.2%) |
| June 2005 | - | $207.00 K(-65.6%) | $7.51 M(-82.4%) |
| Mar 2005 | - | $602.00 K(-89.1%) | $42.59 M(-16.5%) |
| Dec 2004 | $50.98 M(+115.0%) | $5.53 M(+369.7%) | $50.98 M(+12.2%) |
| Sept 2004 | - | $1.18 M(-96.7%) | $45.45 M(+2.7%) |
| June 2004 | - | $35.28 M(+292.3%) | $44.27 M(+392.3%) |
| Mar 2004 | - | $8.99 M | $8.99 M |
| Dec 2003 | $23.71 M(+36.9%) | - | - |
| Dec 2002 | $17.32 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?
- What is Alnylam Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CFF year-on-year change?
What is Alnylam Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ALNY is $172.13 M
What is the all time high annual CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash flow from financing activities is $1.25 B
What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ALNY is $102.75 M
What is the all time high quarterly CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash flow from financing activities is $718.88 M
What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ALNY quarterly cash flow from financing activities has changed by +$63.53 M (+161.94%)
What is Alnylam Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ALNY is $302.39 M
What is the all time high TTM CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM cash flow from financing activities is $1.25 B
What is Alnylam Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ALNY TTM cash flow from financing activities has changed by +$130.26 M (+75.67%)